PMID- 25046660
OWN - NLM
STAT- MEDLINE
DCOM- 20150226
LR  - 20220310
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 136
IP  - 5
DP  - 2015 Mar 1
TI  - Human natural killer cells promote cross-presentation of tumor cell-derived 
      antigens by dendritic cells.
PG  - 1085-94
LID - 10.1002/ijc.29087 [doi]
AB  - Dendritic cells (DCs) cross-present antigen (Ag) to initiate T-cell immunity 
      against most infections and tumors. Natural killer (NK) cells are innate 
      cytolytic lymphocytes that have emerged as key modulators of multiple DC 
      functions. Here, we show that human NK cells promote cross-presentation of tumor 
      cell-derived Ag by DC leading to Ag-specific CD8(+) T-cell activation. 
      Surprisingly, cytotoxic function of NK cells was not required. Instead, we 
      highlight a critical and nonredundant role for IFN-gamma and TNF-alpha production by NK 
      cells to enhance cross-presentation by DC using two different Ag models. 
      Importantly, we observed that NK cells promote cell-associated Ag 
      cross-presentation selectively by monocytes-derived DC (Mo-DC) and CD34-derived 
      CD11b(neg) CD141(high) DC subsets but not by myeloid CD11b(+) DC. Moreover, we 
      demonstrate that triggering NK cell activation by monoclonal antibodies 
      (mAbs)-coated tumor cells leads to efficient DC cross-presentation, supporting 
      the concept that NK cells can contribute to therapeutic mAbs efficiency by 
      inducing downstream adaptive immunity. Taken together, our findings point toward 
      a novel role of human NK cells bridging innate and adaptive immunity through 
      selective induction of cell-associated Ag cross-presentation by CD141(high) DC, a 
      process that could be exploited to better harness Ag-specific cellular immunity 
      in immunotherapy.
CI  - (c) 2014 UICC.
FAU - Deauvieau, Florence
AU  - Deauvieau F
AD  - Inserm UMR-S1052, Centre de Recherche en Cancerologie de Lyon, Lyon, France; CNRS 
      UMR5286, Centre de Recherche en Cancerologie de Lyon, Lyon, France; UNIV UMR1052, 
      Centre de Recherche en Cancerologie de Lyon, Lyon, France; Universite de Lyon, 
      Lyon, France; Centre Leon Berard, Lyon, France.
FAU - Ollion, Vincent
AU  - Ollion V
FAU - Doffin, Anne-Claire
AU  - Doffin AC
FAU - Achard, Carole
AU  - Achard C
FAU - Fonteneau, Jean-Francois
AU  - Fonteneau JF
FAU - Verronese, Estelle
AU  - Verronese E
FAU - Durand, Isabelle
AU  - Durand I
FAU - Ghittoni, Raffaella
AU  - Ghittoni R
FAU - Marvel, Jacqueline
AU  - Marvel J
FAU - Dezutter-Dambuyant, Colette
AU  - Dezutter-Dambuyant C
FAU - Walzer, Thierry
AU  - Walzer T
FAU - Vie, Henri
AU  - Vie H
FAU - Perrot, Ivan
AU  - Perrot I
FAU - Goutagny, Nadege
AU  - Goutagny N
FAU - Caux, Christophe
AU  - Caux C
FAU - Valladeau-Guilemond, Jenny
AU  - Valladeau-Guilemond J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140806
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Antibody-Dependent Cell Cytotoxicity
MH  - Antigen Presentation/*immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Cross-Priming/*immunology
MH  - Dendritic Cells/*immunology/pathology
MH  - Humans
MH  - Immunity, Cellular/*immunology
MH  - Killer Cells, Natural/*immunology/pathology
MH  - Neoplasms/*immunology/pathology
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - NK cell
OT  - cross-presentation
OT  - dendritic cell
OT  - mAb therapy
EDAT- 2014/07/22 06:00
MHDA- 2015/02/27 06:00
CRDT- 2014/07/22 06:00
PHST- 2013/10/08 00:00 [received]
PHST- 2014/06/18 00:00 [accepted]
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2015/02/27 06:00 [medline]
AID - 10.1002/ijc.29087 [doi]
PST - ppublish
SO  - Int J Cancer. 2015 Mar 1;136(5):1085-94. doi: 10.1002/ijc.29087. Epub 2014 Aug 6.